Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENACT Trial
2022-501028-95-00Phase 2Terminated
- Sponsor
- Engrail Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Focal Onset Epilepsy comparing ENX-101 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Responder rate (>=50% reduction in seizure frequency). Started Dec 2022; status: terminated.
02
Drugs
ENX-101
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2022-501028-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501028-95-00.